Crispr Therapeutics Highlights Strategic Priorities And Anticipated 2025 Milestones
Jan 13 (Reuters) -
CRISPR Therapeutics AG ::
*CRISPR THERAPEUTICS HIGHLIGHTS STRATEGIC PRIORITIES AND ANTICIPATED 2025 MILESTONES
*TO ENGAGE REGULATORS ON CTX112 PATH FORWARD, UPDATE MID-2025
*DOSE ESCALATION FOR CTX310 AND CTX320 ONGOING, UPDATES EXPECTED H1 2025
*ONGOING LAUNCH OF CASGEVY DRIVEN BY STRONG PATIENT DEMAND
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 13-JAN-202512:00:00.877 GMT免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。